News

The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...
The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...
Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.
Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...
A federal panel of medical experts on Wednesday recommended an expansion of respiratory syncytial virus (RSV) vaccinations ...
A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...
A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...
A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...
Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...
A vote on April 16 will cover recommendations for three vaccines, including for respiratory syncytial virus and chikungunya, ...
Medicare now covers the RSV vaccine for older adults under Part D, which typically covers prescription drugs. This means you shouldn’t incur any out-of-pocket costs. Respiratory syncytial virus ...
A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...